In-Vitro Toxicology Testing Market

In-Vitro Toxicology Testing Market Size (2021 to 2026)

The size of the global in-vitro toxicology testing market is expected to reach USD 40768 Million by 2026 from USD 21025 Million in 2021, growing at a CAGR of 14.16% from 2021 to 2026.

In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is essential in drug discovery as it identifies the poisonous effects of the new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.

MARKET DRIVERS:

The growing number of technological advancements, rising research & development in cell culture, growing demand for in-vitro toxicology tests over the conventional in-vivo tests are majorly promoting the global in-vitro toxicology testing market growth.

Increasing awareness of toxicity testing studies, expanding health-consciousness amongst individuals, and improving economic status in emerging nations, the existence of favorable regulatory authorities for toxicology testing using in-vitro tests drives the market's growth.

Synergetic relationships between different stakeholders and an increase in toxicology databases facilitating in-vitro test methods are regarded to offer essential growth opportunities for the players in the global in-vitro toxicology testing market. Developing condition-specific makers, tests, and increasing demand for IVD products in existing countries provide significant opportunities for the various stakeholders. GEM, which is Growth Engagement Model, aims to create or control working with the clients to establish new opportunities.

MARKET RESTRAINTS:

However, scarcity of in-vitro models to detect immunostimulants & autoimmunity, lack of predictive ability of in vitro testing over in vivo testing, technological advancements limiting the use & decreasing adoption rate are the significant factors restraining the growth of the in-vitro toxicology testing market.

Impact of COVID-19 on the global in-vitro toxicology testing market:

The widespread novel coronavirus (COVID-19) is an infectious disease that originated in December 2019 in Wuhan, China. The virus has spread to every corner of the world, affecting all business sectors and numerous deaths. With the rise in demand for quick testing and research being organized, the need for in vitro toxicology technologies has accelerated. The FDA's approval for different in-vitro diagnostic kits likes in-vitro diagnostic assays and PCR testing teams and medication for the emergency use in COVID-19 tests and diagnostics. The increasing COVID cases have led to a decrease in the number of patients visiting the hospitals and clinics, which in turn diminished the market growth up to some extent. The need for molecular testing is considered the gold standard for infectious disease diagnosis. The demand was a fight to address the RT-PCR testing, leading to a lack of reagents. Immunoassays are used for the observance of individuals by determining the antibodies against COVID-19. China and the United States authorities have approved a few NGS-based COVID-19 diagnostics for emergency usage. The US FDA has permitted emergency approval for two CRISPR-based diagnostic tests for COVID-19 from the initial stages. The global in-vitro toxicology testing market is forecasted to grow faster during the forecast period with the support received from the COVID-19.

REPORT COVERAGE:

This market research report on the global in-vitro toxicology testing market has been segmented and sub-segmented based on the product, type, toxicity endpoints and tests, method, technology, industry, region.

In-Vitro Toxicology Testing Market – By Product:

• Assays
• Reagents & Labware
• Services
• Growth Hormone Therapy

Based on the product, the Assays segment is estimated to command the largest share of the global in-vitro toxicology testing market during the forecast period. This segment is strongly driven by an increasing number of in-vitro tests being performed worldwide, which leads to the recurrent purchase of reagents and other labware.

In-Vitro Toxicology Testing Market – By Type:

• ADME (Absorption, Distribution, Metabolism, and Excretion)
• Dose
• Toxic Substance

Based on the type, the ADME segment is predicted to stand top in leading max shares in the market during the forecast period due to a growing number of early stages in vitro ADME examining tests in preventing failure.

In-Vitro Toxicology Testing Market – By Toxicity Endpoints & Tests:

• Systemic Toxicity
• Dermal Toxicity
• Carcinogenicity
• Ocular Toxicity
• Skin Sensitization & Irritation
• Genotoxicity
• Neurotoxicity
• Organ Toxicity
• Other Toxicity Endpoints & Tests

Based on Toxicity Endpoints & Tests, the Systemic toxicity segment is estimated to command the largest share of the global in-vitro toxicology testing market as multiple organ development with assumed blood flow for assessing systemic toxicity drives the segment growth.

The Dermal toxicity segment is next in line in having a considerable growth rate throughout the forecast period. Dermal toxicology is simple, easy, reliable, and cost-effective. Moreover, advancement related to dermal toxicity and risk assessment tools is projected to surge the segment growth globally.

In-Vitro Toxicology Testing Market – By Technology:

• OMICS Technologies
• Cell Culture Technology
• High-Throughput Technologies
• Molecular Imaging Technologies 

Based on technology, the cell culture technology segment is projected to dominate the market globally. It is an excellent model for screening toxic effects as it offers consistent samples and reproducible results. Moreover, it supports the tissue-specific function, which urges cell proliferation.

However, the OMICS technologies segment is projected to have the highest CAGR during the forecast period as it provides personalized toxicology data, understanding the toxicity of nano-sized materials.

In-Vitro Toxicology Testing Market – By Method:

• In-Silico Methods
• Biochemical Assays
• Cellular Assays
• Ex-Vivo Models

Based on the method, the In-silico method is estimated to command the largest share of the global in-vitro toxicology testing market by 2019. The wide accessibility of the technology boosts this segment for the pharmacokinetics of drugs. Pharmaceutical and biotechnology companies are important-significantly dependent on cellular assays for toxicity screening.

In-Vitro Toxicology Testing Market – By Industry:

• Cosmetics and Household Products
• Diagnostics
• Pharmaceuticals
• Food Industry
• Chemicals

Based on industry, the cosmetics & household products industry accounted for the largest market share of the global in-vitro toxicology testing market by sector in 2019.

However, the pharmaceutical segment is expected to dominate the market during the forecast period as the rise influences this segment in support of the government. The launch of innovative drugs with advanced technologies is mainly surging the demand for this segment.

The chemical industry is expected to witness lucrative growth over the forecast period due to continuous advancements in toxicity profiling and safety assessment.

In-Vitro Toxicology Testing Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Globally, the European region is estimated to account for the largest share of 32.5% of the global in-vitro toxicology testing market in 2019. In contrast, Asia-Pacific is expected to grow at the highest CAGR of 16.10% during the forecast period.

North America is anticipated to dominate the global IVTT market over the forecast period. Support from government regulations and the adoption of technological advancements are propelling the demand of the market. The U.S. is leading the market in this region because of genetics and genetic screening approaches and the emergence of a new 3D cell culture approach.

Europe is expected to account for the largest share in the In-Vitro toxicology testing market, and Germany is anticipated to dominate and have the largest share in this region. France is expected to grow with the highest CAGR over the forecast period.

Asia-Pacific is estimated to grow with the highest CAGR in the In-Vitro toxicology testing market during the forecast period. The growth is attributed to the emergence of CROs for outsourcing toxicology-relevant research projects and increasing consumer awareness of product safety.

Latin America is expected to have a commendable share in the IVTT. With an increasing number of the aging population, investments in research and development influence the research over the cell culture. Brazil is leading the IVTT market.

The Middle East & Africa region is expected to have small and minimal growth in the IVTT market due to demand for advanced technologies and the appearance of various analytical methods over bioinformatics and biotechnology.

KEY MARKET PARTICIPANTS:

Noteworthy companies operating in the global in-vitro toxicology testing market include Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.), among others.

RECENT MARKET HAPPENINGS:

• On February 20, 2020, Catalent Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced its wholly-owned subsidiary, Catalent Pharma Solutions. 
• On March 27, 2018, BioIVT, a leading provider of biospecimens and related services, announced that it had acquired Ascendance Biotechnology, Inc., which was formed in 2015 from the merger of Hepregen Corporation and the ESI BIO products division of BioTime Inc. to develop a multi-national cell-based company. 
• On December 28, 2016, Ascendance Biotechnology Inc., a leader in the commercialization of In-Vitro cell-based products and stem-related laboratory products, announced the agreement with GE healthcare providing a right to manufacture, market, and sell the GE Healthcare Cytivaof human stem cell-derived and heart muscle cells used for evaluating potential cardiotoxicity. 
• On December 06, 2015, BioTime Inc. regenerative medicine company and Hepregen Corporation announced the formation of Ascendance Biotechnology Inc. Ascendance combines Hepregen’s application–directed, cellular micro-patterning drug and chemical screening technologies with BioTime’s ESI BIO research products and proprietary stem cell-based technologies. 
• On January 31, 2012, Sigma-Aldrich, a leading Life Science and High Technology company, announced that it had completed its acquisition of Bio reliance Holdings Inc., a leading provider of biopharmaceutical testing services, from Avista Capital Partners.